R&D expense · 2011–2025
Vanda Pharmaceuticals R&D expense
$109M+46.8% · FY2025
Vanda Pharmaceuticals (VNDA) reported $109M in R&D expense for fiscal 2025, +46.8% year on year.
| Fiscal year | R&D expense | Change | Filing |
|---|---|---|---|
| FY20252025-12-31 | $109M | +46.8% | Open → |
| FY20242024-12-31 | $74.4M | −3.1% | Open → |
| FY20232023-12-31 | $76.8M | −10.4% | Open → |
| FY20222022-12-31 | $85.8M | +13.8% | Open → |
| FY20212021-12-31 | $75.4M | +35.6% | Open → |
| FY20202020-12-31 | $55.6M | +14.2% | Open → |
| FY20192019-12-31 | $48.6M | +11.6% | Open → |
| FY20182018-12-31 | $43.6M | +13.1% | Open → |
| FY20172017-12-31 | $38.5M | +32.2% | Open → |
| FY20162016-12-31 | $29.2M | +0.0% | Open → |
| FY20152015-12-31 | $29.1M | +51.6% | Open → |
| FY20142014-12-31 | $19.2M | −32.5% | Open → |
| FY20132013-12-31 | $28.5M | −37.7% | Open → |
| FY20122012-12-31 | $45.8M | +57.8% | Open → |
| FY20112011-12-31 | $29.0M | — | Open → |
R&D expense — Research and development expense is what the company charged to R&D in the income statement for the year. Most companies report no R&D at all — the line is absent rather than zero — so this ranking covers the roughly 40% of filers that do.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026 · 2011–2025 compound annual growth +9.9%
R&D expense at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Vanda Pharmaceuticals R&D expense |url=https://companiesranked.com/en/company/vanda-pharmaceuticals/research-and-development-expense |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Vanda Pharmaceuticals R&D expense. CompaniesRanked. https://companiesranked.com/en/company/vanda-pharmaceuticals/research-and-development-expenseBibTeX
@misc{companiesranked-en-company-vanda-pharmaceuticals-research-and-development-expense-2026,
author = {{CompaniesRanked}},
title = {{Vanda Pharmaceuticals R\&D expense}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/vanda-pharmaceuticals/research-and-development-expense}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001628280-26-007460 · February 12, 2026
{{cite web |title=Vanda Pharmaceuticals R&D expense — 10-K (0001628280-26-007460) |url=https://www.sec.gov/Archives/edgar/data/1347178/000162828026007460/vnda-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-12}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.